This week, a breakthrough for heart failure patients with mitral regurgitation emerges, prosthesis-patient mismatch raises the risk of death following TAVR, a new study challenges anticoagulation guidelines, and a possible blessing in disguise for rivaroxaban comes from the massive COMPASS trial. Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Top stories from the American Heart Association scientific sessions
Vascepa gains event-reduction nod; diabetes ups ischemic risks
Post-STEMI events less likely in women; bariatric surgery may lower stroke risk
New trick for old drug; Vascepa cost effective for CV reduction
Card Talk: TAVR and glass ceilings
ISCHEMIA trial, DAPA-HF, and valsartan recall: AHA Special
Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF
Pot heightens stroke, arrhythmia risks; keeping low LDL and BP slashes lifetime heart risk
How risk factors in childhood translate to CV outcomes in adulthood
Driving while defibrillating; hypertension holds greater risk in black patients
AFib hits Native Americans hard; TAVR shown durable, safe after 5 years
Practice changing prevention data from ESC 2019 Part II
Statins tied to skin, soft tissue infections; new Card Talk episode
Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis
Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk
Cardiology dead last as women’s IM subspecialty choice
An antiplatelet surprise; Europeans go low in cholesterol guidelines
SGLT-2 inhibitors and more practice changing data from ESC 2019
Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment
Dapagliflozin transforms into heart failure drug
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive